Monday, Jun 18: 1:15 PM
- 2:30 PM
Monday, June 18, 2018 13:15-14:30
Singapore Convention Center
Room: Hall 405-406
OHBM annual meeting collects over 2,500 abstracts with an overwhelming prevalence of MRI-based works, reflecting the extraordinary development and impact of MR on brain mapping. Only marginal contributions come from other brain imaging modalities, despite major technological advances, or from combination of multiple imaging techniques. different brain imaging communities are today are largely working independent from each other, and one may wonder whether such segregation is really optimal for the advancement of human brain mapping science and for the understanding of the human brain. Yet, limits of each technique and potentials of their combination remain the same. Despite multiple advances in magnet/gradient/antenna/pulse sequence designs, neurotransmission mapping remains out of reach for MR. By contrast, cognitive function mapping is now almost exclusively fMRI-based, but its chronometry can be uncovered only with MEG and EEG. Meanwhile, despite intrinsic limitations in signal penetration, near-infrared imaging is the only approach allowing the study of brain function in a truly ecological environment. These limitations are likely to last for the years to come and the combination of what each technique can provide to the HBM field remains thus of major interest, especially with the advent of “multimodal” instruments such as PET-MRI, MRI-EEG, and NIRS-EEG. Promoting and helping the development of multimodal neuroimaging is thus today a strategic priority for the OHBM council that will be implemented through specific actions such as this first symposium on multimodality during which, speakers from different neuroimaging communities will deliver lectures on state-of-the art multimodal brain mapping methods and applications towards the integration of brain structure, function, dymanics and its neurochemistry. OHBM has the responsibility and the potential for contributing to promote multimodal neuroimaging within its community as well as in other related communities.
Multimodal PET-MRI methods and applications to neurpathologies
Multi-modal EEG/fMRI modeling
Multimodal NIRS-EEG and applications to child epilepsy
Whole human brain mapping community
Alain Dagher, Montreal Neurological Institute, McGill University
Urs Ribary, Simon Fraser University
Bernard Mazoyer, University of Bordeaux
- 1:30 PM
Molecular neuroimaging with Positron Emission Tomography (PET) enables direct in vivo examination of e.g. protein densities and establishment of atlases of molecular targets in the human brain. In addition, one can also investigate, e.g., genetic effects, regulation of receptors, and endogenous neurotransmitter release. Important for drug development, pharmacological interventions, particularly blood-brain barrier passage and target engagement, can be determined. When neurotransmission is modified with drugs or dietary modifications, functional neuroimaging studies with MRI can reveal critical information about the downstream hemodynamic effects on brain circuits. With the development of combined MR-PET equipment that allows for simultaneous data acquisition, a powerful tool has been made available to tap different physio-chemical properties of the brain and this is particularly promising for the assessment of pharmacological or non-pharmacological interventions. In an experimental medicine approach, multimodal neuroimaging allows for identification of specific endophenotypic features predictive of susceptibility to develop, e.g., major depressive disorder.
Gitte Moos Knudsen, igshospitalet and University of Copenhagen
- 1:45 PM
Brain disorders are generally caused by multiple concomitant biological factors. Only causal analyses can potentially lead us to an integrated understanding of pathological progression, clarifying the intrinsic brain multifactorial pathological interactions that take place at different spatiotemporal scales. In this talk, I will discuss about the creation and validation of integrative multimodal neuroimaging and computational models for: i) modeling and understanding pathologic and environmental influences on brain properties and cognition, and ii) identifying effective personalized therapeutic interventions for controlling neurological disorders. Multiple Big-Data application examples in the context of aging and neurodegeneration will be presented.
Yasser Iturria-Medina, Montreal Neurological Institute, McGill University
- 2:00 PM
he EEG/MEG has a unique role to play in Neuroimaging. It EEG in particular has exquisite temporal resolution, is affordable, ecologically valid, and widely deployable. EEG should therefore be a modality of choice for translational research. To contribute to a wider use of EEG in the neuroimaging community we briefly summarize methods and results for EEG/fMRI fusion. Data driven methods rely on regression, variants of ICA or tensor decompositions. Model driven fusion is based on explicit neural mass or field models. Both types of models can be used for both data recorded or concurrently or separately. The latter situation is especially useful in the development of disease progression models and the search for surrogate biomarkers.
Pedro Valdes-Sosa, MD, PhD, DSc, The Clinical Hospital of Chengdu Brain Science Institute/Cuban Neuroscience Center
- 2:15 PM
Functional Near Infrared Spectroscopy (fNIRS) and electroencephalography (EEG) are non-invasive neuroimaging techniques that are highly suitable for clinical and pediatric populations. Although further research and developments are still needed for fNIRS-EEG to be included in the standard clinical care, several applications have been developed and are currently used in clinic. In this presentation, I will show how combined fNIRS-EEG can provide useful information in the presurgical assessment of children with epilepsy, notably for functional brain network mapping and localization of the epileptogenic zone.
Anne Gallagher, Université de Montreal
- 2:30 PM